Optimal Designs for Two-Arm, Phase II Clinical Trial Design with Multiple Constraints

被引:4
|
作者
Mayo, Matthew S. [1 ,2 ]
Mahnken, Jonathan D. [1 ,2 ]
Soong, Seng-jaw [3 ]
机构
[1] Univ Kansas, Med Ctr, Dept Biostat, Kansas City, KS 66103 USA
[2] Univ Kansas, Med Ctr, Ctr Biostat & Adv Informat, Kansas City, KS 66103 USA
[3] Univ Alabama, Biostat & Bioinformat Unit, Birmingham, KS USA
关键词
Optimized design; Sample size; Standard error; Treatment allocation; OPTIMAL ALLOCATION; POWER;
D O I
10.1080/10543400903280597
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Multi-stage Phase II trials are often employed in practice but may not be the best approach when the endpoint of interest is not obtained soon after enrollment and/or when a control arm is desired. We present a new design in which sample size determination includes a control arm and allows for the estimation of response for each treatment as well as estimation of the difference in the response rates. We evaluate this design under varying allocation schemes to treatment arms and response rates for each treatment.
引用
收藏
页码:106 / 124
页数:19
相关论文
共 50 条
  • [1] Bayesian design for two-arm randomized Phase II clinical trials with endpoints from the exponential family using multiple constraints
    Jiang, Wei
    Wick, Jo A.
    He, Jianghua
    Mahnken, Jonathan D.
    Mayo, Matthew S.
    [J]. JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2018, 28 (05) : 824 - 839
  • [2] Generalized optimal design for two-arm, randomized phase II clinical trials with endpoints from the exponential dispersion family
    Jiang, Wei
    Mahnken, Jonathan D.
    He, Jianghua
    Mayo, Matthew S.
    [J]. PHARMACEUTICAL STATISTICS, 2016, 15 (06) : 459 - 470
  • [3] Two-Arm Comparisons in Two-Stage Designs for Stratified Randomized Phase II Trials
    Chang, Yu-Mei
    Shen, Pao-Sheng
    Hsu, Ken-Ning
    [J]. STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2019, 11 (04): : 348 - 359
  • [4] Optimal biased coins for two-arm clinical trials
    Gwise, Thomas E.
    Hu, Jianhua
    Hu, Feifang
    [J]. STATISTICS AND ITS INTERFACE, 2008, 1 (01) : 125 - 135
  • [5] Optimal curtailed designs for single arm phase II clinical trials
    Law, Martin
    Grayling, Michael
    Mander, Adrian P.
    [J]. TRIALS, 2019, 20
  • [6] A two-arm phase 1 clinical trial with NPI-0052, a novel proteasome inhibitor
    Price, Timothy
    Millward, Michael
    Mainwaring, Paul
    Harrison, Simon
    Galley, Laurence
    Townsend, Amanda
    Sukumaran, Shawgi
    Longenecker, Angie
    Palladino, Michael A.
    Lloyd, G. Kenneth
    Neuteboom, Saskia
    Padrik, Peeter
    Spear, Matthew A.
    Spencer, Andrew
    [J]. MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [7] Bayesian Optimal Designs for Multi-Arm Multi-Stage Phase II Randomized Clinical Trials with Multiple Endpoints
    Mulier, Guillaume
    Chevret, Sylvie
    Lin, Ruitao
    Biard, Lucie
    [J]. STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2024, 16 (03): : 315 - 325
  • [8] Comparing an experimental agent to a standard agent: relative merits of a one-arm or randomized two-arm Phase II design
    Taylor, Jeremy Mg
    Braun, Thomas M.
    Li, Zhiguo
    [J]. CLINICAL TRIALS, 2006, 3 (04) : 335 - 348
  • [9] Bayesian sequential monitoring design for two-arm randomized clinical trials with noncompliance
    Shen, Weining
    Ning, Jing
    Yuan, Ying
    [J]. STATISTICS IN MEDICINE, 2015, 34 (13) : 2104 - 2115
  • [10] A Bayesian-frequentist two-stage single-arm phase II clinical trial design
    Dong, Gaohong
    Shih, Weichung Joe
    Moore, Dirk
    Quan, Hui
    Marcella, Stephen
    [J]. STATISTICS IN MEDICINE, 2012, 31 (19) : 2055 - 2067